Study S001956

A Phase 2, Multicenter, Randomised, Paralleled, Placebo-controlled (Double-blind) and Active Drug-controlled (Open) Study to Investigate Efficacy and Safety of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT06148649
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 234
Start: 2023-12-10
Primary completion: 2025-02-27
Lead sponsor: Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HEC88473, Placebo, Dulaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline of HbA1c at week 12 [Baseline to week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.